Skip to main content
SpringerLink
Log in

ACE-Hemmer und Angiotensinrezeptorantagonisten

  • Chapter
Arzneiverordnungs-Report 2007

  • 559 Accesses

Auszug

ACE-Hemmer und Angiotensinrezeptorantagonisten gehören zu den besonders erfolgreichen Arzneimitteln zur Behandlung von Hypertonie, Herz- und Nierenkrankheiten.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Anlauf M, Weber F (2005): Bedeutung der Therapie mit Antihypertensiva für die kardiovaskuläre Prävention. In: Bundesärztekammer (Hrsg.): Fortschritt und Fortbildung in der Inneren Medizin. Band 29. Deutscher Ärzteverlag Köln.

    Google Scholar 

  • Anlauf M. (2006): Beurteilung von Therapien mit der “number needed to treat”. Deutsches Ärzteblatt 103: A3254–A3258.

    Google Scholar 

  • Arzneimittelkommission der Deutschen Ärzteschaft (2004): Empfehlungen zur Therapie der arteriellen Hypertonie. 2. Auflage, Arzneiverordnung in der Praxis, Band 31, Sonderheft 2 (Therapieempfehlungen), Internet: www.akdae. de/35/74_Hypertonie_2004_2Auflage.pdf

    Google Scholar 

  • Barnett AH, Bain SC, Bouter P, Karlberg B et al (2004): Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952–1961.

    Article  PubMed  CAS  Google Scholar 

  • Blood Pressure Lowering Treatment Trialists’ Collaboration (2000): Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356: 1955–1964.

    Article  Google Scholar 

  • Blood Pressure Lowering Treatment Trialists’ Collaboration (2007): Blood Pressure dependent and independent effects of agents that inhibit the renin-angiotensin system. J. Hypertension 25: 951–958.

    Article  CAS  Google Scholar 

  • Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ (2005): Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366: 2026–2033.

    Article  PubMed  CAS  Google Scholar 

  • Cohn JN, Tognoni G for the Valsartan Heart Failure Trial Investigators (2001): A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667–1675.

    Article  PubMed  CAS  Google Scholar 

  • CONSENSUS Trial Study Group (1987): Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429–1435.

    Google Scholar 

  • Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U et al for The LIFE Study Group (2002): Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995–1003.

    Article  PubMed  Google Scholar 

  • Davis BD, Piller LB, Cutler JA, Curt Furberg C et al. (2006): Role of Diuretics in the Prevention of Heart Failure. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 113: 2201–2210.

    Article  PubMed  CAS  Google Scholar 

  • Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTI-MAAL Study Group (2002): Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTI-MAAL randomised trial. Lancet 360: 752–760.

    Article  PubMed  CAS  Google Scholar 

  • Elliott WJ, Meyer PM (2007): Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369: 201–207

    Article  PubMed  CAS  Google Scholar 

  • Fiather MD, Yusuf S, Kober L, Pfeffer M et al (2000): Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355: 1575–1581.

    Article  Google Scholar 

  • Granger CB, McMurray JJV, Yusuf S, Held P et al (2003): Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362: 772–776.

    Article  PubMed  CAS  Google Scholar 

  • Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group (2004): Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363: 2022–2031.

    Article  PubMed  CAS  Google Scholar 

  • Julius S, Nesbitt SD, Egan BM. for the Trial of Preventing Hypertension (TROPHY) Study Investigators (2006): Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 354: 1685–1697.

    Article  PubMed  CAS  Google Scholar 

  • Kizer JR, Dahlöf B, Kjeldsen SE, Julius S et al. (2005): Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol. The Losartan Intervention For Endpoint Reduction in Hypertension Study. Hypertension 45: 46–52.

    PubMed  CAS  Google Scholar 

  • Laverman GD, Navis G, Henning RH, de Jong D, de Zeeuw D (2002): Dual reninangiotensin system blockade at optimal doses for proteinuria. Kidney Int 62: 1020–1025.

    Article  PubMed  CAS  Google Scholar 

  • Levy BI (2004): Can angiotensin II Type 2 receptors have deleterious effects in cardiovascular disease? Circulation 109: 8–13.

    Article  PubMed  Google Scholar 

  • Lewis EJ, Hunsicker LG, Bain RP, Rohde RD for the Collaborative Study Group (1993): The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456–1462.

    Article  PubMed  CAS  Google Scholar 

  • Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al for the SCOPE Study Group (2003): The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21: 875–886.

    Article  PubMed  CAS  Google Scholar 

  • Malacco E, Santonastaso M, Vari NA, Gargiulo A, Spagnuolo V, Bertocchi F, Palatini P; Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study (2004): Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 26: 855–865.

    Article  PubMed  CAS  Google Scholar 

  • Mann JF, Ritz E, Kunz R (2006): Renoprotective effects of renin-angiotensin-system inhibitors. Lancet 367: 900.

    Article  PubMed  Google Scholar 

  • Maschio G, Albert D, Ganin G, Locatelli F, Mann JFE et al (1996): Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334: 939–945.

    Article  PubMed  CAS  Google Scholar 

  • McMurray JJV, Östergren J, Swedberg K, Granger CB et al (2003): Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362: 767–771.

    Article  PubMed  CAS  Google Scholar 

  • Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME (2000): Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan And Lisinopril Microalbuminuria (CALM) Study. Brit Med J 321: 1440–1444.

    Article  PubMed  CAS  Google Scholar 

  • National National Collaborating Centre for Chronic Conditions (2006): Hypertension: management of hypertension in adults in primary care: partial update. London: Royal College of Physicians. Internet: http://guidance.nice.org.uk/ CG34/guidance/pdf/English

    Google Scholar 

  • Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J-L et al for the Valsartan in Acute Myocardial Infarction Trial Investigators (2003a): Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893–1906.

    Article  PubMed  CAS  Google Scholar 

  • Pfeffer MA, Swedberg K, Granger CB, Held P et al (2003b): Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362: 559–766.

    Google Scholar 

  • Pitt B, Poole-Wilson PA, Segal R, Martinez FA et al (2000): Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial — the Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582–1587.

    Article  PubMed  CAS  Google Scholar 

  • Pitt B (2004): ACE inhibitors for patients with vascular disease without left ventricular dysfunction — may they rest in PEACE? N Engl J Med 351: 2115–2117.

    Article  PubMed  CAS  Google Scholar 

  • PROGRESS Collaborative Group (2001): Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033–1041.

    Article  Google Scholar 

  • Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP et al for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators (2004): Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351: 1941–1951.

    Article  PubMed  CAS  Google Scholar 

  • Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V et al (1990): A comparison of the efficacy and safety of abeta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 150: 1707–1713.

    Article  PubMed  CAS  Google Scholar 

  • Schmieder RE, Hilgers KF, Schlaich MP, Schmidt MW (2007): Renin-angiotensin system and cardiovascular risk. Lancet 369: 1208–1219.

    Article  PubMed  CAS  Google Scholar 

  • Schrader J, Lüders S, Kulschewski A, Hammersen F et al. for the MOSES Study Group (2005): Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention Principal Results of a Prospective Randomized Controlled Study (MOSES). Stroke 36:1218–1226.

    Article  PubMed  CAS  Google Scholar 

  • Svensson P, de Faire U, Sleight P, Yusuf S, Jan Östergren J (2001): Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 38: e28–e32.

    Article  PubMed  CAS  Google Scholar 

  • Teo KK, Yusuf S, Pfeffer M, Torp-Pedersen C, Kober L, Hall A et al and the ACE Inhibitors Collaborative Group (2002): Effects of long-term treatment with angiotensin-converting enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 360: 1037–1043.

    Article  PubMed  CAS  Google Scholar 

  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002): Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997.

    Article  Google Scholar 

  • The DREAM Trial Investigators (2006): Effect of ramipril on the incidence of diabetes. N Engl J Med 355: 1551–1562.

    Article  Google Scholar 

  • The GISEN Group (1997): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857–1863.

    Article  Google Scholar 

  • The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000): Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342: 145–153.

    Article  Google Scholar 

  • Verma S, Strauss M (2004): Angiotensin receptor blockers and myocardial infarction. These drugs may increase myocardial infarction — and patients may need to be told. BMJ 329: 1248–1249.

    Article  PubMed  Google Scholar 

  • Wachteil K, Hornestam B, Lehto M, Slotwiner DJ et al (2005a): Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 45: 705–711.

    Article  Google Scholar 

  • Wachtell K, Lehto M, Gerdts E, Olsen MH et al (2005b): Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 45: 712–719.

    Article  PubMed  CAS  Google Scholar 

  • White HD (2003): Commentary. Candesartan and heart failure: the allure of CHARM. Lancet 362: 754–755.

    Article  PubMed  Google Scholar 

  • Wing LMH, Reid MC, Ryan P, Beilin LJ et al for the Second Australian National Blood Pressure Study Group (2003): A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348: 583–592.

    Article  PubMed  CAS  Google Scholar 

  • Yusuf S (2002): From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 89(2A): 18A–25A.

    Article  PubMed  Google Scholar 

  • Yusuf S, Pfeffer MA, Swedberg K, Granger CB et al (2003): Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362: 777–781.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Friedrich-Plettke-Weg 12, 27570, Bremerhaven

    Prof. Dr. med. Manfred Anlauf

Authors
  1. Prof. Dr. med. Manfred Anlauf
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK Schleswig-Holstein Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Anlauf, M. (2008). ACE-Hemmer und Angiotensinrezeptorantagonisten. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2007. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72548-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-72548-0_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-72547-3

  • Online ISBN: 978-3-540-72548-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation